Maiwei Biological (688062.SH): The clinical trial application for 9MW5211 injection has been approved by the National Medical Products Administration.

Zhtng Cijng APP news, Maiwei Biological (688062.SH) announced that recently, the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for 9MW5211 injection for the indication of multiple sclerosis (MS) has been approved. In addition, the clinical trial application for its use in inflammatory bowel disease (IBD) has been approved by the National Medical Products Administration and FDA respectively. The company is also actively advancing the applications for clinical trials for several other indications, with some applications already accepted by the National Medical Products Administration.